Price$15.06+5.14 (+51.80%)
2026-03-052026-06-08
News · 26 weeks58+140%
2025-12-142026-06-07
Mix2990d
- Other18(62%)
- SEC Filings9(31%)
- Insider1(3%)
- Analyst1(3%)
Latest news
25 items- SECSEC Form SCHEDULE 13G filed by Akari Therapeutics plcSCHEDULE 13G - Akari Therapeutics Plc (0001541157) (Subject)
- SECSEC Form DEF 14A filed by Akari Therapeutics plcDEF 14A - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Releases CEO Corner Reflecting on Evolving ADC Landscape and Akari's Differentiated PH1 Payload Platform Following ASCO 2026Discussion highlights growing importance on novel ADC payloads, and Akari's ASCO data in KRAS-driven cancers and future potential Access the Akari CEO Corner here TAMPA, Fla. and LONDON, June 04, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today released a new CEO Corner segment featuring President and Chief Executive Officer Abizer Gaslightwala discussing key themes emerging from the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and Akari's positioning within the evolving ADC landscape. In the segment, Mr. Gaslightwala reflects
- SECSEC Form D filed by Akari Therapeutics plcD - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Discusses Breakthrough Potential of AKTX-101 and Novel Spliceosome-Modulating ADC Platform in Virtual Investor "What This Means" Segment Following ASCO Abstract AcceptanceCEO Abizer Gaslightwala highlights promising ASCO data demonstrating synergy of AKTX-101 with adagasrib in KRAS-driven cancers Watch the "What This Means" video here TAMPA, Fla. and LONDON, May 28, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that its CEO participated in a Virtual Investor "What This Means" interview focused on the Company's recently accepted abstract at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. During the interview, Mr. Gaslightwala highlighted the significance of Akari's first ASCO abst
- SECSEC Form PRE 14A filed by Akari Therapeutics plcPRE 14A - Akari Therapeutics Plc (0001541157) (Filer)
- SECAkari Therapeutics plc filed SEC Form 8-K: Entry into a Material Definitive Agreement8-K - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Announces $5.5 Million Private Placement OfferingTAMPA, Fla. and LONDON, May 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the successful pricing of a private placement financing round. This transaction is expected to raise an aggregate of approximately $5.5 million in gross proceeds. With these funds the Company will focus on advancing its lead ADC program utilizing its unique RNA splicing modulator payload, AKTX-101, toward a first-in-human Phase 1 clinical trial. "This financing reflects deep conviction from our long-term strategic investors and positions Akari to build on our
- SECSEC Form RW filed by Akari Therapeutics plcRW - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form 10-Q filed by Akari Therapeutics plc10-Q - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form NT 10-Q filed by Akari Therapeutics plcNT 10-Q - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics to Present at A.G.P.'s Annual Healthcare Company ShowcaseLive webcast fireside chat with Abizer Gaslightwala, President and Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here TAMPA, Fla. and LONDON, May 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced that Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics, will participate in a fireside chat at A.G.P.'s Annual Healthcare Company Showcase being held virtually on Wednesday, May 20, 2026. Management will discuss the Company's differentiated ADC pipeline, including progress across i
- PRAkari Therapeutics Secures Key European Patent For Its Novel RNA Splicing Modulator ADC Payload, Strengthening Global IP Estate For All Major Global MarketsTAMPA, Fla. and LONDON, May 12, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the grant of a major European patent that significantly strengthens its global intellectual property position and underscores the differentiation of its proprietary PH1 ADC payload platform. The newly granted patent (European Patent No. 3684773B1), titled "Thailanstatin Analogs," provides broad composition-of-matter protection for Akari's proprietary Thailanstatin-based payloads, engineered for use in highly targeted cytotoxic ADC therapies. The claims encompa
- SECSEC Form S-1 filed by Akari Therapeutics plcS-1 - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Secures Australian Patent Approval, Further Expanding Global Protection of Its Proprietary PH1 RNA Splicing Modulator ADC PayloadPatent covers proprietary 2nd generation Thailanstatin analog payload designed for use in ADCs (antibody-drug conjugates) targeting cancerApproval strengthens Akari's global intellectual property across all major markets and supports advancement of AKTX-101 and ADC pipeline TAMPA, Fla. and LONDON, April 27, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulator payloads, today announced the acceptance of an Australian patent covering its core payload technology, and further expanding protection of its proprietary ADC platform. The accepted patent (Application No. 20242
- PRAkari Therapeutics ASCO Abstract Acceptance Highlights Potential for AKTX-101 ADC to Treat KRAS Mutant TumorsExpands potential opportunities for AKTX-101 and its novel RNA splicing modulator payload in additional tumors beyond current Phase 1 plan Publication to be made available online on May 21, 2026 at 5:00 PM ET TAMPA, Fla. and LONDON, April 21, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads, today announced that its abstract has been accepted for online publication at the American Society of Clinical Oncology (ASCO) Annual Meeting 2026. This marks Akari's first abstract acceptance at ASCO, one of the most highly regarded forums in clinical oncology rese
- PRAkari Therapeutics Reports Positive Preclinical Data for AKTX-101 Demonstrating Differentiated Cytotoxicity for First-in-Class TROP2 ADC Payload Targeting RNA SplicingSuperior potency demonstrated versus leading TROP2 ADCs across bladder, lung and breast tumor models Novel RNA spliceosome-targeting payload PH1 shows potential to overcome Topoisomerase I inhibitor resistance Preclinical data support advancement of AKTX-101 into Phase 1 studies in a rapidly evolving TROP2 ADC class expected to reach ~$12B by 20331 TAMPA, Fla. and LONDON, April 20, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with a novel RNA splicing modulator payload, today announced the presentation of positive preclinical data for its lead TROP2-targeting ADC, AKTX-101, at the America
- SECSEC Form EFFECT filed by Akari Therapeutics plcEFFECT - Akari Therapeutics Plc (0001541157) (Filer)
- SECSEC Form POS AM filed by Akari Therapeutics plcPOS AM - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Participates in Virtual Investor "What This Means" Interview Discussing Strategic Partnership with WuXi XDCCEO Abizer Gaslightwala discusses the Company's strategic partnership with WuXi XDC and its implications for platform validation and development acceleration Company highlights accelerated IND timeline for AKTX-101 and positioning within the rapidly evolving ADC landscape Watch the "What This Means" video here TAMPA and LONDON, April 09, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads, today announced that Abizer Gaslightwala, Director, President and CEO of Akari Therapeutics, participated in a Virtual Investor "What This Means" interview focused on t
- ANALYSTAkari Therapeutics downgraded by Maxim GroupMaxim Group downgraded Akari Therapeutics from Buy to Hold
- PRAkari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA SplicingTAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splicing modulating payloads announced a strategic partnership with WuXi XDC, a global leader in ADC development and manufacturing, to accelerate the development of Akari's novel PH1 payload. "This strategic partnership with WuXi XDC represents a major milestone for Akari and a powerful validation of our novel PH1 payload technology," said Abizer Gaslightwala, President and Chief Executive Officer of Akari Therapeutics. "WuXi XDC is widely recognized as a global leader in ADC innovation, and with this
- SECAmendment: SEC Form F-6/A filed by Akari Therapeutics plcF-6/A - Akari Therapeutics Plc (0001541157) (Subject)
- SECSEC Form 10-K filed by Akari Therapeutics plc10-K - Akari Therapeutics Plc (0001541157) (Filer)
- PRAkari Therapeutics Announces Abstract Accepted for Poster Presentation at the American Association for Cancer Research Annual Meeting 2026TAMPA, Fla. and LONDON, March 18, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ:AKTX), an oncology biotechnology company developing antibody drug conjugates (ADCs) with novel RNA splice modulating payloads, today announced its abstract has been accepted for poster presentation at the American Association for Cancer Research Annual Meeting 2026, being held April 17–22, 2026. Details of the poster presentation are as follows: Title: Rationale for the development of a differentiated Trop2 ADC in solid tumors of the bladder, lung, and breastPoster Number: 3179Poster Board Number: 14Session Category: Experimental and Molecular TherapeuticsSession Title: Targeting Cell Surface Vulne
AKTX FAQ
6 questionsWhat does Akari Therapeutics plc do?
Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in...Where does AKTX stock trade?
Akari Therapeutics plc (AKTX) is listed on NASDAQ.What sector and industry is AKTX in?
Akari Therapeutics plc operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.What are analysts saying about AKTX?
Akari Therapeutics plc has had 3 recent analyst actions on file. The most recent action was from Maxim Group: Hold on 2026-04-08. Recent price targets range from $100.00 to $500.00.What companies are similar to AKTX?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare AKTX side-by-side with any of them on Quantisnow.How can I track AKTX on Quantisnow?
Quantisnow aggregates Akari Therapeutics plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow AKTX to receive live email and push alerts on every new disclosure.